Roxine Staats
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roxine Staats has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Michele Vendruscolo
Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK
3 shared publications - Robert I. Horne
University of Cambridge
2 shared publications - Alexander John Dear
Department of Biology, Institute of Biochemistry, ETH Zurich, Zurich, Switzerland
1 shared publication - Alexander Kai Buell
Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark
1 shared publication - Alisdair Stevenson
Department of Biology, Institute of Biochemistry, ETH Zurich, Otto Stern Weg 3, 8093 Zurich, Switzerland
1 shared publication Andrea Possenti
University of Cambridge
1 shared publication
Latest Publications
- Open Access
Global kinetic model of lipid-induced α -synuclein aggregation and its inhibition by small molecules
The aggregation of α -synuclein into amyloid fibrils is a hallmark of Parkinson’s disease. This process has been shown to directly involve interactions between proteins and lipid surfaces when the latter are present. Despite this importance, the molecular mechanisms of lipid-induced amyloid aggregation have remained largely elusive. Here, we present a global kinetic model to describe lipid-induced amyloid aggregation of α -synuclein. Using this framework we find that α -synuclein fibrils form via a two-step primary nucleation mechanism and that lipid molecules are directly involved in both the nucleation and fibril elongation steps, giving rise to lipid-protein coaggregates. To illustrate the applicability of this kinetic approach to drug discovery, we identify the mechanism of action of squalamine, a known inhibitor of α-synuclein aggregation, finding that this small molecule reduces the rate of lipid-dependent primary nucleation. Our work will likely guide the rational design of α -synuclein aggregation inhibitors. Significance Statement: Amyloid aggregation is a hallmark of a diverse range of diseases including Parkinson’s Disease, where the protein α -synuclein is a major con-stituent of proteinaceous deposits found in patients. It is well established that interactions between α -synuclein and lipids modulate aggregation. However, the molecular mechanisms driving this lipid-induced aggregation have remained largely elusive, which has frustrated so far the discovery of drugs that prevent lipid-induced aggregation. In this work, we present the first global kinetic model describing lipid-induced aggregation and by integrating this theoretical framework with in vitro experimental data of lipid-induced α -synuclein aggregation, we reveal the role of lipid membranes in the aggregation process and uncover the mechanism by which small molecule inhibitors interfere with this process.
Open AccessGlobal kinetic model of lipid-induced α -synuclein aggregation and its inhibition by small molecules
The aggregation of α -synuclein into amyloid fibrils is a hallmark of Parkinson’s disease. This process has been shown to directly involve interactions between proteins and lipid surfaces when the latter are present. Despite this importance, the molecular mechanisms of lipid-induced amyloid aggregation have remained largely elusive. Here, we present a global kinetic model to describe lipid-induced amyloid aggregation of α -synuclein. Using this framework we find that α -synuclein fibrils form via a two-step primary nucleation mechanism and that lipid molecules are directly involved in both the nucleation and fibril elongation steps, giving rise to lipid-protein coaggregates. To illustrate the applicability of this kinetic approach to drug discovery, we identify the mechanism of action of squalamine, a known inhibitor of α-synuclein aggregation, finding that this small molecule reduces the rate of lipid-dependent primary nucleation. Our work will likely guide the rational design of α -synuclein aggregation inhibitors. Significance Statement: Amyloid aggregation is a hallmark of a diverse range of diseases including Parkinson’s Disease, where the protein α -synuclein is a major con-stituent of proteinaceous deposits found in patients. It is well established that interactions between α -synuclein and lipids modulate aggregation. However, the molecular mechanisms driving this lipid-induced aggregation have remained largely elusive, which has frustrated so far the discovery of drugs that prevent lipid-induced aggregation. In this work, we present the first global kinetic model describing lipid-induced aggregation and by integrating this theoretical framework with in vitro experimental data of lipid-induced α -synuclein aggregation, we reveal the role of lipid membranes in the aggregation process and uncover the mechanism by which small molecule inhibitors interfere with this process.
- Open Access
- 19 January 2022
- Published by Springer Nature in Research Square
A Machine Learning Approach to Identify Small Molecule Inhibitors of Secondary Nucleation in α-Synuclein Aggregation
Drug development is an increasingly active area of application of machine learning, prompted by the need to overcome the high attrition rates of conventional drug discovery pipelines. This issue is especially pressing for neurodegenerative diseases, where disease-modifying drugs are not widely available yet. To address this problem, we describe an approach based on a combination of machine learning with chemical kinetics to target diseases caused by protein misfolding and aggregation. We use this approach to identify specific inhibitors of the proliferation of α-synuclein aggregates through secondary nucleation, a process implicated in Parkinson’s disease. Our results demonstrate that this approach leads to the identification of novel chemical matter with an improved hit rate and potency over more traditional approaches.
- 19 January 2022
- Published by Springer Nature in Research Square
Open AccessA Machine Learning Approach to Identify Small Molecule Inhibitors of Secondary Nucleation in α-Synuclein Aggregation
Drug development is an increasingly active area of application of machine learning, prompted by the need to overcome the high attrition rates of conventional drug discovery pipelines. This issue is especially pressing for neurodegenerative diseases, where disease-modifying drugs are not widely available yet. To address this problem, we describe an approach based on a combination of machine learning with chemical kinetics to target diseases caused by protein misfolding and aggregation. We use this approach to identify specific inhibitors of the proliferation of α-synuclein aggregates through secondary nucleation, a process implicated in Parkinson’s disease. Our results demonstrate that this approach leads to the identification of novel chemical matter with an improved hit rate and potency over more traditional approaches.
- Open Access
- 18 December 2020
- Published by Springer Nature in Communications Chemistry
- Vol. 3 (1) , 1-9
Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter
The aggregation of α-synuclein is a central event in Parkinsons’s disease and related synucleinopathies. Since pharmacologically targeting this process, however, has not yet resulted in approved disease-modifying treatments, there is an unmet need of developing novel methods of drug discovery. In this context, the use of chemical kinetics has recently enabled accurate quantifications of the microscopic steps leading to the proliferation of protein misfolded oligomers. As these species are highly neurotoxic, effective therapeutic strategies may be aimed at reducing their numbers. Here, we exploit this quantitative approach to develop a screening strategy that uses the reactive flux toward α-synuclein oligomers as a selection parameter. Using this approach, we evaluate the efficacy of a library of flavone derivatives, identifying apigenin as a compound that simultaneously delays and reduces the formation of α-synuclein oligomers. These results demonstrate a compound selection strategy based on the inhibition of the formation of α-synuclein oligomers, which may be key in identifying small molecules in drug discovery pipelines for diseases associated with α-synuclein aggregation.
- 18 December 2020
- Published by Springer Nature in Communications Chemistry
- Vol. 3 (1) , 1-9
Open AccessScreening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter
The aggregation of α-synuclein is a central event in Parkinsons’s disease and related synucleinopathies. Since pharmacologically targeting this process, however, has not yet resulted in approved disease-modifying treatments, there is an unmet need of developing novel methods of drug discovery. In this context, the use of chemical kinetics has recently enabled accurate quantifications of the microscopic steps leading to the proliferation of protein misfolded oligomers. As these species are highly neurotoxic, effective therapeutic strategies may be aimed at reducing their numbers. Here, we exploit this quantitative approach to develop a screening strategy that uses the reactive flux toward α-synuclein oligomers as a selection parameter. Using this approach, we evaluate the efficacy of a library of flavone derivatives, identifying apigenin as a compound that simultaneously delays and reduces the formation of α-synuclein oligomers. These results demonstrate a compound selection strategy based on the inhibition of the formation of α-synuclein oligomers, which may be key in identifying small molecules in drug discovery pipelines for diseases associated with α-synuclein aggregation.